157 related articles for article (PubMed ID: 33799370)
1. Analysis of Different Types of Interferon-Associated Retinopathy in Patients with Chronic Hepatitis C Virus Infection Treated with Pegylated Interferon Plus Ribavirin.
Wu CM; Su FH; Muo CH; Huang JC; Wu MM; Yeh CC
Viruses; 2021 Mar; 13(3):. PubMed ID: 33799370
[TBL] [Abstract][Full Text] [Related]
2. Retinal vascular complications associated with interferon-ribavirin therapy for chronic hepatitis C: A population-based study.
Lai CH; Yang YH; Chen PC; King YC; Liu CY
Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):191-198. PubMed ID: 29210149
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan.
Chang YK; Tseng YT; Chen KH; Chen KT
BMC Endocr Disord; 2019 Apr; 19(1):36. PubMed ID: 30953492
[TBL] [Abstract][Full Text] [Related]
4. Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection.
Su TH; Liu CJ; Tseng TC; Chou SW; Liu CH; Yang HC; Wu SJ; Chen PJ; Chen DS; Chen CL; Kao JH
Aliment Pharmacol Ther; 2019 Feb; 49(3):331-339. PubMed ID: 30592071
[TBL] [Abstract][Full Text] [Related]
5. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
Mousa N; Besheer T; Gad Y; Elbendary A; Mokbel T; Abdel-Aziz A
J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin.
Fouad YM; Khalaf H; Ibraheem H; Rady H; Helmy AK
Int J Infect Dis; 2012 Jan; 16(1):e67-71. PubMed ID: 22115957
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
[TBL] [Abstract][Full Text] [Related]
8. Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse.
Labarga P; Vispo E; Barreiro P; Rodríguez-Novoa S; Pinilla J; Morello J; Martín-Carbonero L; Tuma P; Medrano J; Soriano V
J Acquir Immune Defic Syndr; 2010 Mar; 53(3):364-8. PubMed ID: 20101191
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.
Hu CC; Lin CL; Kuo YL; Chien CH; Chen SW; Yen CL; Lin CY; Chien RN
Aliment Pharmacol Ther; 2013 Jan; 37(1):81-90. PubMed ID: 23121150
[TBL] [Abstract][Full Text] [Related]
10. Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis.
Dolatimehr F; Karimi-Sari H; Rezaee-Zavareh MS; Alavian SM; Behnava B; Gholami-Fesharaki M; Sharafi H
Daru; 2017 Apr; 25(1):11. PubMed ID: 28427463
[TBL] [Abstract][Full Text] [Related]
11. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort.
Liu TW; Tsai PC; Huang CI; Tsai YS; Wang SC; Ko YM; Lin CC; Chen KY; Liang PC; Lin YH; Hsieh MY; Hou NJ; Huang CF; Yeh ML; Lin ZY; Chen SC; Dai CY; Chuang WL; Huang JF; Yu ML
J Formos Med Assoc; 2018 Jan; 117(1):54-62. PubMed ID: 28389143
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
Sulkowski MS; Fessel WJ; Lazzarin A; Berenguer J; Zakharova N; Cheinquer H; Côté P; Dieterich D; Gadano A; Matthews G; Molina JM; Moreno C; Pineda JA; Pulido F; Rivero A; Rockstroh J; Hernandez D; McPhee F; Eley T; Liu Z; Mendez P; Hughes E; Noviello S; Ackerman P
Hepatol Int; 2017 Mar; 11(2):188-198. PubMed ID: 28210927
[TBL] [Abstract][Full Text] [Related]
13. Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients.
Ronzoni L; Aghemo A; Rumi MG; Prati G; Colancecco A; Porretti L; Monico S; Colombo M; Cappellini MD
J Viral Hepat; 2014 Jun; 21(6):416-23. PubMed ID: 24750239
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C.
Okuse C; Yotsuyanagi H; Nagase Y; Kobayashi Y; Yasuda K; Koike K; Iino S; Suzuki M; Itoh F
World J Gastroenterol; 2006 Jun; 12(23):3756-9. PubMed ID: 16773695
[TBL] [Abstract][Full Text] [Related]
15. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
[TBL] [Abstract][Full Text] [Related]
16. Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer.
Su TH; Tseng TC; Liu CJ; Chou SW; Liu CH; Yang HC; Chen PJ; Chen DS; Chen CL; Kao JH
Int J Cancer; 2020 Aug; 147(3):901-908. PubMed ID: 31853972
[TBL] [Abstract][Full Text] [Related]
17. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
[TBL] [Abstract][Full Text] [Related]
18. A longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C.
Tavakoli-Tabasi S; Bagree A
J Clin Gastroenterol; 2012 Feb; 46(2):162-7. PubMed ID: 21814144
[TBL] [Abstract][Full Text] [Related]
19. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
He LL; Chen Z; Chen Y; Xu H; Tang H; Lei BJ; Lei XZ
Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan.
Lin JA; Chen YC; Cheng SN; Chen PJ; Chu HC; Hsieh TY; Shih YL
J Formos Med Assoc; 2014 Oct; 113(10):727-33. PubMed ID: 24231092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]